Read More

ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones

ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.

ADCT